LAMIVUDINE and ZIDOVUDINE
- Product NDC
- 50268-456
- 11-digit product format
- 502680456
- Labeler code
- 50268
- Product ID
- 50268-456_d5ddc7ce-e6a9-a0fa-e053-2995a90a0d4b
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- LAMIVUDINE and ZIDOVUDINE
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- AvPAK
- Application
- ANDA079124
- Marketing category
- ANDA
- Marketing start
- 2020-05-12
- Marketing end
- 0000-00-00
- Substance
- LAMIVUDINE; ZIDOVUDINE
- Active strength
- 150 mg/1; mg/1
- Pharmacologic classes
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleoside Reverse Transcriptase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2023-12-31
- Current FDA listing
- Historical FDA.report record
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 50268-456-12 | 50268045612 | 20 BLISTER PACK in 1 BOX (50268-456-12) > 1 TABLET, FILM COATED in 1 BLISTER PACK (50268-456-11) | 20 blister pack | 2020-05-12 | 0000-00-00 | No | No | Current |